FDA Expands Harvoni Use in HCV Patients with Advanced Liver Disease

10 Questions to Ask Your Doctor About Rheumatoid Arthritis
February 16, 2016
MS Relapse, Remission States Seen to Differ in Gene Expression Between Men and Women
February 16, 2016
Show all

FDA Expands Harvoni Use in HCV Patients with Advanced Liver Disease

The Food and Drug Administration (FDA) just added approval for Harvoni (ledipasvir/sofosbuvir) to be used for chronic hepatitis C patients with advanced liver disease.

Gilead announced that the Food and Drug Administration (FDA) has approved new indications for Harvoni (ledipasvir/sofosbuvir) for use in chronic hepatitis C patients with advanced liver disease.

Harvoni in combination with ribavirin for 12 weeks is now approved for use in chronic hepatitis C virus (HCV) genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for HCV genotype 1-infected patients with decompensated cirrhosis (Child-Pugh B/C), including those who have undergone liver transplantation.

The FDA approval was based on data from the Phase 2, open-label SOLAR-1 and SOLAR-2 trials. They evaluated 12 and 24 weeks of treatment with Harvoni in combination with ribavirin in HCV treatment-naive and treatment-experienced patients with genotype 1 and 4 infection who had undergone liver transplantation and/or who had decompensated liver disease. Pooled data showed that sustained virologic response at Week 12 (SVR12) among genotype 4 HCV post-transplant patients without cirrhosis, or with compensated cirrhosis, were similar to the reported genotype 1 SVR12 rates.

The expanded indications allow Harvoni to be used in more patient populations, including HCV genotypes 1, 4, 5, and 6, HCV/HIV-1 co-infection, HCV genotype 1 and 4 liver transplant recipients, and genotype 1-infected patients with decompensated cirrhosis.

Read Full Article: FDA Expands Harvoni Use in HCV Patients with Advanced Liver Disease – MPR

Comments are closed.